Sygnature Discovery’s scientific teams have extensive experience in this therapeutic area and have successfully delivered 5 clinical compounds and 4 preclinical compounds for our clients.
As a result of this experience, Sygnature’s teams are familiar with Medicinal Chemistry strategies to target drug delivery to the lung for a broad range of respiratory diseases, including infection (viral and fungal), inflammatory (severe Asthma and COPD) and lung remodelling (IPF). For each therapeutic area and drug target, our medicinal chemistry design strategy, supported by the synthesis of bespoke compounds, seeks in the first instance, potency and duration of exposure in the lung. We use in vitro bioscience and DMPK assays to rank order compounds and enhance the chances of in vivo success. We appreciate what makes a good inhaled medicine.
Our highly experienced scientists utilise state-of-the-art technologies and are adept at developing bespoke assays, or adapting existing assays as necessary to meet project needs. We have experience in developing in vitro assays utilising airway epithelial cells, endothelial cells, and alveolar macrophages.
Our mixed occupancy laboratories allow our integrated project teams involving Chemistry, DMPK, Computational Chemistry and Bioscience to work closely together with our clients to find the best solution to their current and future project requirements. This close collaboration between the disciplines results in accelerated design-make-test-analyse (DMTA) cycles, to rapidly identify Structure-Activity Relationships (SAR), enable efficient compound optimisation and Candidate Drug delivery. We offer a broad range of assay platforms and systems that provide a flexible approach to respiratory disease drug discovery and can be used to discover or profile new or existing targets, identify potential new medicines or novel mechanisms with the potential to impact the disease processes of interest.
Sygnature Discovery’s many assay platforms and systems include:
- Biophysics to explore potential protein or epigenetic targets and protein-protein interactions.
- Gene expression.
- Measurement of secreted or cellular inflammatory mediators.
- Cellular assays.
- Cellular imaging platforms.
In addition, we have our own in-house human Blood Donor Panel, allowing easy access to immune and inflammatory cells from volunteer blood and can access additional ethically-sourced patient samples, including airway epithelial cells, endothelial cells and alveolar macrophages, through links with local hospitals, universities and commercial vendors.